• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

德国 2 型糖尿病门诊患者的风险因素控制较差:DIAbetes COhoRtE(DIACORE)研究。

Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COhoRtE (DIACORE) study.

机构信息

Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.

Diabetologische Schwerpunktpraxis Dres. Segiet, Gleixner und Bode, Speyer, Germany.

出版信息

PLoS One. 2019 Mar 21;14(3):e0213157. doi: 10.1371/journal.pone.0213157. eCollection 2019.

DOI:10.1371/journal.pone.0213157
PMID:30897159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6428304/
Abstract

INTRODUCTION

Patients with diabetes mellitus type 2 (DM2) are at high risk for micro- and macrovascular disease. Here, we explore the degree of traditional risk factor control in the baseline visit of a cohort of DM2 outpatients.

METHODS

DIACORE (DIAbetes COhoRtE) is a prospective cohort study of 3000 adult DM2 outpatients. Here, we present results from the baseline visit. Sociodemographic and anthropometric variables, cardiovascular risk factors, comorbidities and medication were assessed by interview and medical exams. Serum-creatinine based estimated glomerular filtration rate (eGFRcrea) and urinary albumin-creatinine ratio (UACR) were determined for classification of chronic kidney disease (CKD). The proportion of patients with adequate control of traditional risk factors (blood pressure<140/90mmHg, HbA1c<7.5%, LDL<100mg/dl) was calculated in 2892 patients with non-missing data in 9 relevant variables within each KDIGO 2012 CKD class.

RESULTS

In the analyzed baseline data (n = 2892, 60.2% men), mean (standard deviation) values for age, DM2 duration and HbA1c were 65.3 (9.3) years, 10.3 (8.4) years and 6.9% (1.1) respectively. Of these 2892 patients, 18.7% had CKD stage 3 or higher, 25.7% had UACR≥30mg/g. Adequate blood pressure, HbA1c and LDL control was achieved in 55.7%, 78.5% and 34.4%, respectively. In 16.4% of patients (473), all three risk factors were below recommended targets. The proportion of adequate risk factor control was similar across KDIGO eGFRcrea classes. Adequate blood pressure and HbA1c control were significantly associated with lower UACR category without and with controlling for other risk factors (p<0.0001, p = 0.0002, respectively).

CONCLUSION

In our study of patients with diabetes mellitus type 2, we observed a low level of risk factor control indicating potential for risk reduction.

摘要

简介

2 型糖尿病(DM2)患者存在微血管和大血管疾病的高风险。在这里,我们探讨了一组 DM2 门诊患者基线就诊时的传统危险因素控制程度。

方法

DIACORE(糖尿病队列研究)是一项对 3000 例成年 DM2 门诊患者的前瞻性队列研究。在这里,我们呈现基线就诊时的结果。通过访谈和体检评估社会人口统计学和人体测量学变量、心血管危险因素、合并症和药物。通过血清肌酐估计肾小球滤过率(eGFRcrea)和尿白蛋白肌酐比(UACR)确定慢性肾脏病(CKD)的分类。在 KDIGO 2012 CKD 各分类中,对 2892 例无缺失 9 项相关变量的患者,计算了传统危险因素(血压<140/90mmHg、HbA1c<7.5%、LDL<100mg/dl)控制充分的患者比例。

结果

在分析的基线数据(n=2892,60.2%为男性)中,年龄、DM2 病程和 HbA1c 的平均值(标准差)分别为 65.3(9.3)岁、10.3(8.4)年和 6.9%(1.1)。在这 2892 例患者中,18.7%患有 CKD 3 期或更高阶段,25.7%患者 UACR≥30mg/g。血压、HbA1c 和 LDL 控制充分的患者分别占 55.7%、78.5%和 34.4%。在 16.4%(473 例)患者中,所有三种危险因素均低于推荐目标。在 KDIGO eGFRcrea 分类中,适当危险因素控制的比例相似。在不考虑其他危险因素和考虑其他危险因素的情况下,血压和 HbA1c 控制充分与较低的 UACR 类别显著相关(p<0.0001,p=0.0002)。

结论

在我们对 2 型糖尿病患者的研究中,我们观察到危险因素控制水平较低,表明存在降低风险的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/6428304/b09d99d6f84e/pone.0213157.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/6428304/5c2fef4e0fd9/pone.0213157.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/6428304/b09d99d6f84e/pone.0213157.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/6428304/5c2fef4e0fd9/pone.0213157.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/6428304/b09d99d6f84e/pone.0213157.g002.jpg

相似文献

1
Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COhoRtE (DIACORE) study.德国 2 型糖尿病门诊患者的风险因素控制较差:DIAbetes COhoRtE(DIACORE)研究。
PLoS One. 2019 Mar 21;14(3):e0213157. doi: 10.1371/journal.pone.0213157. eCollection 2019.
2
Study design of DIACORE (DIAbetes COhoRtE) - a cohort study of patients with diabetes mellitus type 2.DIACORE(糖尿病队列研究)研究设计 - 2 型糖尿病患者的队列研究。
BMC Med Genet. 2013 Feb 14;14:25. doi: 10.1186/1471-2350-14-25.
3
Association of sleep-disordered breathing with diabetes-associated kidney disease.睡眠呼吸障碍与糖尿病相关性肾病的关联
Ann Med. 2017 Sep;49(6):487-495. doi: 10.1080/07853890.2017.1306100. Epub 2017 Mar 27.
4
Annual deterioration of renal function in hypertensive patients with and without diabetes.患有和未患糖尿病的高血压患者肾功能的年度恶化情况。
Vasc Health Risk Manag. 2017 Jun 26;13:231-237. doi: 10.2147/VHRM.S135253. eCollection 2017.
5
Development and Validation of a Prediction Model for Future Estimated Glomerular Filtration Rate in People With Type 2 Diabetes and Chronic Kidney Disease.开发和验证 2 型糖尿病和慢性肾脏病患者未来估算肾小球滤过率的预测模型。
JAMA Netw Open. 2023 Apr 3;6(4):e231870. doi: 10.1001/jamanetworkopen.2023.1870.
6
Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study.肾小球滤过率较高的2型糖尿病患者肾功能迅速下降,随后肾小球滤过率受损:日本糖尿病并发症研究。
J Diabetes Complications. 2017 Feb;31(2):473-478. doi: 10.1016/j.jdiacomp.2016.06.020. Epub 2016 Jun 29.
7
Cardiovascular and Renal Outcomes in Patients with Type-2 Diabetes and Chronic Kidney Disease Identified in a United States Administrative Claims Database: A Population Cohort Study.在美国行政索赔数据库中确定的 2 型糖尿病和慢性肾脏病患者的心血管和肾脏结局:一项人群队列研究。
Nephron. 2021;145(4):342-352. doi: 10.1159/000513782. Epub 2021 Mar 31.
8
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.达格列净对 2 型糖尿病患者心血管结局的影响根据基线肾功能和蛋白尿状态:一项随机临床试验的预设二次分析。
JAMA Cardiol. 2021 Jul 1;6(7):801-810. doi: 10.1001/jamacardio.2021.0660.
9
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.卡格列净在 KDIGO 风险类别中的心血管和肾脏结局的相对和绝对风险降低:CANVAS 计划的结果。
Am J Kidney Dis. 2021 Jan;77(1):23-34.e1. doi: 10.1053/j.ajkd.2020.06.018. Epub 2020 Sep 21.
10
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.钠-葡萄糖协同转运蛋白 2 抑制剂达格列净在 2 型糖尿病合并 3b-4 期慢性肾脏病患者中的作用。
Nephrol Dial Transplant. 2018 Nov 1;33(11):2005-2011. doi: 10.1093/ndt/gfx350.

引用本文的文献

1
Exploring Molecular Signatures Associated with Inflammation and Angiogenesis in the Aqueous Humor of Patients with Non-Proliferative Diabetic Retinopathy.探索非增殖性糖尿病视网膜病变患者房水中与炎症和血管生成相关的分子特征。
Int J Mol Sci. 2025 Jul 4;26(13):6461. doi: 10.3390/ijms26136461.
2
Development and Validation of a Prediction Model for Future Estimated Glomerular Filtration Rate in People With Type 2 Diabetes and Chronic Kidney Disease.开发和验证 2 型糖尿病和慢性肾脏病患者未来估算肾小球滤过率的预测模型。
JAMA Netw Open. 2023 Apr 3;6(4):e231870. doi: 10.1001/jamanetworkopen.2023.1870.
3
External validation of six clinical models for prediction of chronic kidney disease in a German population.

本文引用的文献

1
Liraglutide and Renal Outcomes in Type 2 Diabetes.利拉鲁肽与 2 型糖尿病患者的肾脏结局。
N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.
2
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
3
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
在德国人群中对六种用于预测慢性肾脏病的临床模型进行外部验证。
BMC Nephrol. 2022 Aug 1;23(1):272. doi: 10.1186/s12882-022-02899-0.
4
Scoring model to predict risk of chronic kidney disease in Chinese health screening examinees with type 2 diabetes.用于预测中国健康体检 2 型糖尿病患者发生慢性肾脏病风险的评分模型。
Int Urol Nephrol. 2022 Jul;54(7):1629-1639. doi: 10.1007/s11255-021-03045-9. Epub 2021 Nov 1.
5
The Protective Roles and Molecular Mechanisms of Troxerutin (Vitamin P4) for the Treatment of Chronic Diseases: A Mechanistic Review.芦丁(维生素 P4)治疗慢性疾病的保护作用和分子机制:机制研究综述。
Curr Neuropharmacol. 2021;19(1):97-110. doi: 10.2174/1570159X18666200510020744.
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
4
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.恩格列净与 2 型糖尿病患者的肾脏疾病进展。
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
5
[New aspects in prevention and therapy of diabetic nephropathy].
Dtsch Med Wochenschr. 2016 Feb;141(3):186-9. doi: 10.1055/s-0041-109591. Epub 2016 Feb 3.
6
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净:在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
7
Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes.2型糖尿病患者血糖控制及心血管结局的随访
N Engl J Med. 2015 Sep 3;373(10):978. doi: 10.1056/NEJMc1508386.
8
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.2 型糖尿病患者的血压降低和血糖控制的随访。
N Engl J Med. 2014 Oct 9;371(15):1392-406. doi: 10.1056/NEJMoa1407963. Epub 2014 Sep 19.
9
[Diabetic nephropathy: new insights into diagnosis, prevention and treatment].[糖尿病肾病:诊断、预防及治疗新见解]
Dtsch Med Wochenschr. 2014 Apr;139(14):704-6. doi: 10.1055/s-0034-1369841. Epub 2014 Mar 25.
10
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.2 型糖尿病强化生活方式干预的心血管效应。
N Engl J Med. 2013 Jul 11;369(2):145-54. doi: 10.1056/NEJMoa1212914. Epub 2013 Jun 24.